ロード中...
Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious
BACKGROUND: A median progression free survival (PFS) of 18–20 months and median overall survival (OS) of 51–57 months can be achieved with the use of imatinib, in metastatic or advanced gastrointestinal stromal tumor (GIST). Sunitinib and regorafenib are approved options for patients progressing on...
保存先:
| 出版年: | J Gastrointest Oncol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AME Publishing Company
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4963378/ https://ncbi.nlm.nih.gov/pubmed/27563456 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.03.06 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|